Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 24192927)

1.

A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.

Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, Jennings TA, Otto GA, Donahue A, He J, Palmer G, Ali S, Nahas M, Young G, Labrecque E, Frampton G, Erlich R, Curran JA, Brennan K, Downing SR, Yelensky R, Lipson D, Hawryluk M, Miller VA, Stephens PJ.

Clin Cancer Res. 2014 Jan 1;20(1):68-75. doi: 10.1158/1078-0432.CCR-13-1992. Epub 2013 Nov 5.

2.

Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.

Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, Sun J, He J, Curran JA, Ali S, Yelensky R, Lipson D, Palmer G, Miller VA, Stephens PJ.

Clin Cancer Res. 2013 May 15;19(10):2668-76. doi: 10.1158/1078-0432.CCR-13-0295. Epub 2013 Apr 10.

3.

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.

Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, He J, Palmer G, Yelensky R, Lipson D, Ali S, Balasubramanian S, Curran JA, Garcia L, Mahoney K, Downing SR, Hawryluk M, Miller VA, Stephens PJ.

Mod Pathol. 2014 Feb;27(2):271-80. doi: 10.1038/modpathol.2013.135. Epub 2013 Jul 26.

4.

Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.

Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, Cheville JC.

Mod Pathol. 2014 May;27(5):758-64. doi: 10.1038/modpathol.2013.201. Epub 2013 Nov 1.

5.

HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization.

Ching CB, Amin MB, Tubbs RR, Elson P, Platt E, Dreicer R, Fergany A, Hansel DE.

Mod Pathol. 2011 Aug;24(8):1111-9. doi: 10.1038/modpathol.2011.69. Epub 2011 Apr 22.

6.

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.

Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ.

Gynecol Oncol. 2013 Sep;130(3):554-9. doi: 10.1016/j.ygyno.2013.06.019. Epub 2013 Jun 20.

7.

ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.

Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, Le Corre D, Benhaim L, Pallier K, Aust D, Pistorius S, Blons H, Svrcek M, Laurent-Puig P.

Eur J Cancer. 2014 Jul;50(10):1740-6. doi: 10.1016/j.ejca.2014.04.007. Epub 2014 May 2.

PMID:
24797764
8.

Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.

Li J, Jackson CL, Yang D, Noble L, Wheeler M, MacKenzie D, Adegun T, Amin A.

Target Oncol. 2014 Oct 8. [Epub ahead of print]

PMID:
25293577
9.

The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.

Lin X, Zhu B, Villa C, Zhong M, Kundu S, Rohan SM, Yang XJ.

Hum Pathol. 2014 Sep;45(9):1824-9. doi: 10.1016/j.humpath.2014.04.015. Epub 2014 May 8.

PMID:
24993315
10.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L.

Oncologist. 2014 May;19(5):453-8. doi: 10.1634/theoncologist.2013-0377. Epub 2014 Apr 7.

11.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.

Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.

12.

Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.

Ross JS, Wang K, Rand JV, Sheehan CE, Jennings TA, Al-Rohil RN, Otto GA, Curran JC, Palmer G, Downing SR, Yelensky R, Lipson D, Balasubramanian S, Garcia L, Mahoney K, Ali SM, Miller VA, Stephens PJ.

Am J Surg Pathol. 2014 Feb;38(2):235-8. doi: 10.1097/PAS.0000000000000102.

PMID:
24418857
13.

Micropapillary variant of urothelial carcinoma: a report of 4 cases and literature review.

Cheng YT, Luo HL, Sung MT, Chiang PH.

Chang Gung Med J. 2010 Jul-Aug;33(4):461-5. Review.

14.

Clinical significance of micropapillary urothelial carcinoma of the upper urinary tract.

Sung HH, Cho J, Kwon GY, Jeon HG, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.

J Clin Pathol. 2014 Jan;67(1):49-54. doi: 10.1136/jclinpath-2013-201799. Epub 2013 Aug 12.

PMID:
23940135
15.

High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues.

Chaux A, Cohen JS, Schultz L, Albadine R, Jadallah S, Murphy KM, Sharma R, Schoenberg MP, Netto GJ.

Hum Pathol. 2012 Oct;43(10):1590-5. doi: 10.1016/j.humpath.2011.11.016. Epub 2012 Mar 9.

16.

Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.

Young G, Wang K, He J, Otto G, Hawryluk M, Zwirco Z, Brennan T, Nahas M, Donahue A, Yelensky R, Lipson D, Sheehan CE, Boguniewicz AB, Stephens PJ, Miller VA, Ross JS.

Cancer Cytopathol. 2013 Dec;121(12):688-94. doi: 10.1002/cncy.21338. Epub 2013 Jul 24.

PMID:
23893923
17.

Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder?

Amsellem-Ouazana D, Bièche I, Molinié V, Elie C, Vieillefond A, Tozlu S, Botto H, Debré B, Lidereau R.

Eur Urol. 2006 Jun;49(6):1035-42; discussion 1042-3. Epub 2006 Jan 30.

PMID:
16466848
18.

No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas.

Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, Dodurga Y, Bagci H, Duzcan SE.

Pathol Oncol Res. 2008 Sep;14(3):261-6. doi: 10.1007/s12253-008-9027-y. Epub 2008 Apr 16.

PMID:
18415713
19.

Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.

Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist YK, Klose H, Marx AH, Koops S, Simon R, Izbicki JR, Bokemeyer C, Sauter G, Wilczak W.

Mod Pathol. 2012 Dec;25(12):1566-73. doi: 10.1038/modpathol.2012.125. Epub 2012 Aug 17.

20.

Micropapillary urothelial carcinoma of the renal pelvis: report of a case and review of the literature.

Munakata S, Tahara H, Kojima K, Kishimoto T.

Med Sci Monit. 2007 Apr;13(4):CS47-52. Review.

PMID:
17392655
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk